]> 2026-04-12T02:24:23-07:00 Carboplatin 0 en Carboplatin is generally preferred over cisplatin due to its significantly lower toxicity profile, though myelosuppression remains a concern. The combination with Talazoparib is under study to determine the safety and tolerability of this novel therapeutic approach. 2025-01-18T08:26:45Z 2460693.8519097 Carboplatin 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","Carboplatin, especially in combination with agents like Talazoparib, represents a promising line of investigation for recurrent GBM and high-grade glioma. Early research suggests variable efficacy, with the potential for meaningful clinical benefit in specific patient populations."] Carboplatin# ERR0de0b09fdf871942cb9b8a10a8978dce 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Carboplatin's role in treating recurrent glioma, including GBM, is under active exploration, with early studies and ongoing trials investigating its efficacy and safety in combination with other therapeutic agents. Its lower toxicity profile compared to other platinum-based chemotherapies, like cisplatin, makes it an attractive option for recurrent glioma treatment strategies, pending further evidence from current research efforts."] Carboplatin# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name